MyoKardia Inc (MYOK.OQ)
21 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2016||Interim Non-Executive Chairman of the Board, Lead Independent Director|
|44||2013||President, Chief Executive Officer, Director|
|2018||Chief Financial Officer|
|51||2017||Chief Operating Officer|
|54||2014||Senior Vice President - Nonclinical and Pharmaceutical Development|
- BRIEF-MyoKardia Says Offering 3.75 Mln Common Shares
- BRIEF-MyoKardia Says Phase 3 Explorer-Hcm Study Evaluating Mavacamten To Initiate In Q2 2018
- BRIEF-MyoKardia Doses First Patient In Pioneer Open-Label Extension Study Of Mavacamten
- BRIEF-MyoKardia Q1 Loss Per Share $0.50
- BRIEF-MyoKardia Begins Dosing In Phase 2 MAVERICK-HCM Clinical Trial Of Mavacamten